Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes

Abstract

Immunohistochemistry for mismatch repair protein expression is widely used as a surrogate for microsatellite instability status-an important signature for immunotherapy and germline testing. There are no systematic analyses examining the sensitivity of immunohistochemistry for microsatellite instability-high status. Mismatch repair immunohistochemistry and microsatellite instability testing were performed routinely as clinically validated assays. We classified germline/ somatic mutation types as truncating (nonsense, frameshift, in/del) versus missense and predicted pathogenicity of the latter. Discordant cases were compared to concordant groups: microsatellite instability-high/ mismatch repair-deficient for mutation comparison and microsatellite stable/ mismatch repair-proficient for immunohistochemical comparison. 32 of 443 (7%) microsatellite instability-high cases had immunohistochemistry. Four additional microsatellite instability-high research cases had discordant immunohistochemistry. Of 36 microsatellite instability-high cases with discordant immnohistochemistry, 30 were mismatch repair-proficient while 6 (5 MLH1 and 1 MSH2) retained expression of the defective mismatch repair protein and lost its partner. In microsatellite instability-high tumors with discordant immunohistochemistry, we observed an enrichment in deleterious missense mutations over truncating mutations, with nearly 70% (25/36) of cases having pathogenic germline or somatic missense mutations, as opposed to only 17% (6/36) in a matched microsatellite instability-high group with concordant immunohistochemistry (p=0.0007). In microsatellite instability-high cases with discordant immunohistochemistry and MLH1 or PMS2 abnormalities, less cells showed expression (p=0.015 and p=0.00095 respectively) compared to microsatellite stable/ mismatch repair-proficient cases. Tumor mutation burden, MSIsensor score, and truncating mismatch repair gene mutations were similar between microsatellite instability-high cases with concordant versus discordant immunohistochemical Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:

Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

“…2b ). It is well-known that the MMR pathway is an important way to influence point mutation 30 . Thus, qRT-PCR analysis was employed to identify MMR genes.…”

A Novel Germline MLH1 In-Frame Deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon Isolated PMS2 Loss in Tumor Tissue

“…Deletions resulting in C-terminal truncation of MLH1 with retained immunoreactivity have been reported earlier [46,47], cautioning genetic counselors to search for MLH1 mutations in cases of isolated PMS2 loss when family history is highly suspicious for MLH1, and not a PMS2 defect. Additionally, a recent paper by Hechtman et al [48], showed an enrichment of deleterious missense variants over truncating variants in immunohistochemically discordant, MSI-H cases mostly involving MLH1.…”

MiMSI - a deep multiple instance learning framework improves microsatellite instability detection from tumor next-generation sequencing

“…Further, we show MiMSI can detect MSI-H phenotype that occurs concurrently with other genomic lesions such as exonuclease domain mutations in POLE, where the MSI phenotype may not be clearly apparent. Finally, MMR IHC has a sensitivity of approximately 94% results can show false-retained MMR protein patterns with pathogenic missense mutations, removing an indication for treatment with immune checkpoint inhibition and points to the need for sensitive testing methods 15 .…”

“…Mutational signature analysis attributed 72% of the mutations to the deficiency of DNA polymerase-ε (POLE) resulting from an exonuclease domain mutation (V411L). 15% of the mutations were attributable to MMR deficiency and there was a nonsense mutation in MSH2 (E580*), suggesting the possibility of a smaller clone with MMR phenotype that was either not clear during IHC review or MSH2 expression was retained 15 . The two other discrepant cases were MSS by MiMSI score but MSI-H by orthogonal IHC/PCR.…”